The Journal of Headache and Pain (Dec 2022)
Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
- Andreas R. Gantenbein,
- Reto Agosti,
- Christian P. Kamm,
- Gunther Landmann,
- Niklaus Meier,
- Gabriele Susanne Merki-Feld,
- Jens A. Petersen,
- Heiko Pohl,
- Philippe Ryvlin,
- Christoph J. Schankin,
- Dragana Viceic,
- Chiara Zecca,
- Elisabeth Schäfer,
- Ina Meyer,
- Michael E. Arzt
Affiliations
- Andreas R. Gantenbein
- Department of Neurology and Neurorehabilitation, ZURZACH Care
- Reto Agosti
- Kopfwehzentrum Hirslanden
- Christian P. Kamm
- Department of Neurology, Inselspital, University Hospital Bern and University of Bern
- Gunther Landmann
- Center for Pain Medicine
- Niklaus Meier
- Department of Neurology, Spital Thun
- Gabriele Susanne Merki-Feld
- Department of Reproductive Endocrinology, University Hospital Zurich
- Jens A. Petersen
- Neurozentrum Bern
- Heiko Pohl
- Department of Neurology, University Hospital Zurich
- Philippe Ryvlin
- Department of Clinical Neurosciences, CHUV
- Christoph J. Schankin
- Department of Neurology, Inselspital, University Hospital Bern and University of Bern
- Dragana Viceic
- Private Practice
- Chiara Zecca
- Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale (EOC)
- Elisabeth Schäfer
- Department of Neurology and Neurorehabilitation, ZURZACH Care
- Ina Meyer
- Novartis Pharma Schweiz AG
- Michael E. Arzt
- Novartis Pharma Schweiz AG
- DOI
- https://doi.org/10.1186/s10194-022-01530-9
- Journal volume & issue
-
Vol. 23,
no. 1
pp. 1 – 2
Abstract
No abstracts available.
